- Home
- ThronePR
Author
ThronePR
New York City Custom Jewelry CadCamNYC Modeling to Create High-End Jewelry
Thu, May 24, 2018 00:04 ET
New York Jewelry Designer and Manufacturer – Using the Latest 3D Technology to Create High-End Custom Jewelry for Designers and Artists
Jibrel is Licensed as Financial Intermediary by VQF
Mon, May 21, 2018 22:32 ET
The Jibrel Network provides traditional financial assets, such as currencies, bonds and equities, as standard ERC-20 tokens on the Ethereum blockchain.
TGV Therapeutics working with NIH on novel anti-fungal against deadly C.auris
Thu, Feb 15, 2018 13:37 ET
Early tests indicate effectiveness against dangerous new superbug fungus
Robotics Market Leader AITHEON Launches Token Presale, Headlines BTC Miami
Thu, Jan 18, 2018 14:58 ET
AITHEON, the AI market leader, announced today it launched its worldwide token presale. The announcement was made at the North American Blockchain Conference.
Jado Crown Focuses On The Sequence of 12, Sacred Geometry In Jado Crown Ring
Thu, Jan 18, 2018 14:47 ET
The Jado Crown Ring is elegant, stylish, and oh so versatile; it may just be the only ring collection you’ll ever need.
NY Scientists First To Link Neurodegenerative Diseases And Bacterial Viruses
Mon, Oct 16, 2017 16:05 ET
Alzheimer’s and other diseases can be caused by viruses in gut microbiota. This discovery may change conventional understanding of causes for many diseases.
Human Microbiology Institute:Bacteriophages May Cause Neurodegenerative Diseases
Wed, Jul 12, 2017 14:32 ET
Viruses called bacteriophages affect bacteria in mammal gut environment and may cause human diseases, a study from Human Microbiology Institute reveals
TGV-inhalonix's New Study Shows Promise To Fight Deadly CF Lung Infections
Fri, Jun 9, 2017 11:20 ET
New York-based company says its drug candidate demonstrates breakthrough results against pathogens that cause lethal infections in cystic fibrosis patients
TGV-inhalonix's New Drug To Help Patients With Resistant Fungal Lung Infections
Thu, May 11, 2017 13:55 ET
The New York drug development company says its Mul-1867 drug candidate shows high potential for treating cystic fibrosis and other severe lung infections.